East Bay biotech with late-stage drug files for bankruptcy
February 19, 2019 at 17:30 PM EST
Over 28 years, the company spent a half-billion dollars on developing inhaled lung-disease drugs that fell short of FDA approval.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.